Imatinib, a PDGFRα antagonist, treats asthma by decreasing mast cell activation in patients; imatinib also decreases MCP1 expression in mice (Berlin and Lukacs, 2005; Cahill et al., 2017). Here, CCL2 is linked to asthma.